Standard BioTools Inc. Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Standard BioTools Inc. (LAB) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $52.40 million as of 2016-03-31, per its 10-Q filed 2016-05-09.
Discontinued › Notes › Investments › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2016-05-09
- 2016-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $52.40M.
- 2015-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $68.30M.
- 2015-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $76.30M.
- 2015-03-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $79.50M.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2016-03-31 | $52.40M 10-Q · filed 2016-05-09 |
| 2015-09-30 | $68.30M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $76.30M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $79.50M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $81.60M 10-K · filed 2015-02-26 |
| 2014-09-30 | $64.30M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $51.10M 10-Q · filed 2014-08-04 |
| 2014-03-31 | $42.10M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $49.10M 10-K · filed 2014-03-12 |
| 2013-09-30 | $43.60M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $29.00M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $17.80M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $22.90M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |